Yıl: 2013 Cilt: 59 Sayı: 4 Sayfa Aralığı: 330 - 337 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Günümüzde ve gelecekte osteoporoz tedavisi

Öz:
Osteoporoz, ülkelerin nüfuslarının yaşlanması ile giderek artan önemli bir sağlık problemidir. Osteoporozun tedavisinde, günümüzde ve gelecekteprimer amaç kırıkların önlenmesidir. Osteoporotik kırıkların önlenmesindeantirezorbtif ve anabolik ajanlar olmak üzere geniş bir aralıkta ilaç grubu vardır. Nanoteknolojik ve farmakogenetik alandaki çalışmalarla osteoporozda tanı ve tedavi hızla gelişmektedir. Yeni tedavi seçenekleri, modelleri ve stratejilerininamacı, kemik formasyonunu arttırmak ve aşırı kemik rezorbsiyonunu önlenmektir. Medikal tedavinin yanısıra kullanılan fizik tedavi ve rehabilitasyon yöntemleri bilgisayar teknolojisindeki gelişmelerle orantılı olarak hastaların yaşam kalitesini artırmada önemli bir rol oynamaya devam edecektir.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Osteoporosis treatment at present and in the future

Öz:
Osteoporosis is a growing health problem with the aging of the World’spopulation. The primary goal of osteoporosis treatment at present and in the future is to prevent fractures. A wide range of medications including both antiresorptive and anabolic agents are available for the prevention of fractures. The diagnosis and treatment of osteoporosis are progressing rapidly in parallel with the research studies in the field of nanotechnology and pharmacogenetics. The aim of the new treatment options, modalities, and strategies is to increase bone formation and to inhibit excessive resorption. Besides medical treatment, correspondingly with the progress in computer technology, physical therapy and rehabilitation modalities will continue to play an important role in improving the quality of life of patients with osteoporosis.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013;44:125-35.
  • 2. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87.
  • 3. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly 2012;142:13624.
  • 4. Deal CL, Abelson AG, Carey JJ. Management of osteoporosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, weisman MH, editors. Rheumatology. 4th ed. Philadelphia: Mosby Elsevier; 2008. p. 1955-68.
  • 5. Sindel D, Ketenci A. Osteoporozda klinik bulgular ve görüntüleme. İçinde: Ataman Ş, Peyman Y, editörler. Romatoloji Kitabı. Ankara: MN Medikal&Nobel Tıp Kitabevi; 2012. s. 1125-40.
  • 6. Sindel D. Tanı ve ayırıcı tanı. İçinde: Gökçe-Kutsal Y, editör. Osteoporoz Cep Kitabı, Ankara: Güneş Kitabevi; 2005. s. 69-87.
  • 7. Sindel D. Sekonder osteoporoz. İçinde: Gökçe-Kutsal Y, editör. Modern Tıp Seminerleri: 19, Osteoporoz. Ankara: Güneş Kitabevi; 2001. s. 66-81.
  • 8. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2013.
  • 9. Lentle B, Cheung AM, Hanley DA, Leslie WD, Lyons D, Papaioannou A, et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J 2011;62:243-50.
  • 10. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
  • 11. Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, et al. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011;14:240-62.
  • 12. FRAX WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/ FRAX/
  • 13. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
  • 14. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:136.
  • 15. Body JJ, Bergmann P Boonen S, Boutsen Y, Devogelaer JP Goemaere S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:1657-80.
  • 16. Lecart MP Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 2011;12:2533-52.
  • 17. Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013;7:435-48.
  • 18. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
  • 19. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 2013;24:567-80.
  • 20. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P Meunier PJ, Lyons RA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40-9.
  • 21. Zhu K, Prince RL. Calcium and bone. Clin Biochem 2012;45:936-42.
  • 22. Holick MF Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
  • 23. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
  • 24. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222-30.
  • 25. Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med 2013;11:303.
  • 26. Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP Diez-Perez A, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012;91:225-43.
  • 27. Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L. Male osteoporosis: A review. World J Orthop 2012;3:223-34.
  • 28. Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604.
  • 29. Hadji P The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric 2012;15:513-23.
  • 30. D’Amelio P Isaia GC. The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother 2013;14:949-56.
  • 31. Hamdy RC, Daley DN. Oral calcitonin. Int J Womens Health 2012;4:471-9.
  • 32. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 2012;27:1821-9.
  • 33. http://www.ema.europa.eu/ema/index.
  • 34. http://www.iegm.gov.tr.
  • 35. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother 2013.
  • 36. Diab DL, Watts NB. Denosumab in osteoporosis. Expert Opin Drug Saf 2013.
  • 37. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
  • 38. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010;25:1886-94.
  • 39. Bone HG, Chapurlat R, Brandi ML, Brown JP Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483-92.
  • 40. Esbrit P Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol 2013;85:1417-23.
  • 41. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 2012;97:311-25.
  • 42- Okazaki M, Ferrandon S, Vilardaga JP Bouxsein ML, Potts JT Jr, Gardella TJ. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A 2008;105:16525-30.
  • 43. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009;21:380-5.
  • 44. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F Wattel A, Kamel S, et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 2009;284:575-84.
  • 45. Cianferotti L, D’Asta F Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2013;5:127-39.
  • 46. Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP Benhamou CL, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012;23:1115-22.
  • 47. Marini F Brandi ML. The future of pharmacogenetics for osteoporosis. Pharmacogenomics 2013;14:641-53.
  • 48. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/ beta-catenin signaling. J Bone Miner Res 2009;24:1651-61.
  • 49. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo- controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
  • 50. Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2013.
  • 51. Costa AG, Bilezikian JP Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 2012;10:64-72.
  • 52. Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med 2011;12:263-73.
  • 53. Kimura S, Nakagawa T, Matsuo Y, Ishida Y, Okamoto Y, Hayashi M. JTT- 305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol 2011;668:331-6.
  • 54. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995;206:89-96.
  • 55. Gelb BD, Shi GP Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
  • 56. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-8.
  • 57. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging 2012;7:235-47.
  • 58. Ohlsson C. Bone metabolism in 2012: Novel osteoporosis targets. Nat Rev Endocrinol 2013;9:72-4.
  • 59. Pérez-Castrillón JL, Pinacho F De Luis D, Lopez-Menendez M, Dueñas Laita A. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos 2010;2010.
  • 60. Zerbini CA, McClung MR. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. Ther Adv Musculoskelet Dis 2013;5:199-209.
  • 61. Engelke K, Nagase S, Fuerst T, Small M, Kuwayama T, Deacon S, et al. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res 2013.
  • 62. Henriksen DB, Alexandersen P Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2007;40:723-9.
  • 63. Askov-Hansen C, Jeppesen PB, Lund P Hartmann B, Holst JJ, Henriksen DB. Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regul Pept 2013;181:4-8.
  • 64. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012;366:2048-51.
  • 65. Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 2013;5:107-11.
  • 66. Guan M, Yao W, Liu R, Lam KS, Nolta J, Jia J, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012;18:456-62.
  • 67. Price CT, Koval KJ, Langford JR. Silicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosis. Int J Endocrinol 2013;2013:316783.
  • 68. Spector TD, Calomme MR, Anderson SH, Clement G, Bevan L, et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord 2008;9:85.
  • 69. Sindel D. Osteoporozda rehabilitasyon. Osteoporoz Kitabı. İstanbul: Epsilon Matbaası; 2002. s.122-34.
  • 70. Oral A, Küçükdeveci AA, Varela E, Ilieva EM, Valero R, Berteanu M, et al. Osteoporosis. The role of physical and rehabilitation medicine physicians. The European perspective based on the best evidence. A paper by the UEMS-PRM Section Professional Practice Committee. Eur J Phys Rehabil Med 2013;49:565-77.
  • 71. Howe TE, Shea B, Dawson LJ, Downie F Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011;CD000333.
  • 72. Slatkovska L, Alibhai SM, Beyene J, Cheung AM. Effect of whole- body vibration on BMD: a systematic review and meta-analysis. Osteoporos Int 2010;21:1969-80.
  • 73. Lau RW, Liao LR, Yu F Teo T, Chung RC, Pang MY. The effects of whole body vibration therapy on bone mineral density and leg muscle strength in older adults: a systematic review and meta-analysis. Clin Rehabil 2011;25:975-88.
  • 74. Sindel D. Osteoporozun önlenmesi (Prevansiyonu). Osteoporoz Kitabı. İstanbul: Epsilon Matbaası; 2002. s.87-92.
  • 75. Sindel D, Dilşen G, Kubat A. Postmenopozal osteoporozda rehabilitasyon açısından yaşam kalitesi sonuçları. Romatol Tıp Rehab 1995;6:144-8.
  • 76. Zhang JD, Poffyn B, Sys G, Uyttendaele D. Comparison of vertebroplasty and kyphoplasty for complications. Orthop Surg 2011;3:158-60.
  • 77. Lamy O, Uebelhart B, Aubry-Rozier B. Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures. Osteoporos Int 2013.
  • 78. Han S, Wan S, Ning L, Tong Y, Zhang J, Fan S. Percutaneous vertebroplasty versus balloon kyphoplasty for treatment of osteoporotic vertebral compression fracture: a meta-analysis of randomised and non-randomised controlled trials. Int Orthop 2011;35:1349-58.
APA SİNDEL D (2013). Günümüzde ve gelecekte osteoporoz tedavisi. , 330 - 337.
Chicago SİNDEL Dilşad Günümüzde ve gelecekte osteoporoz tedavisi. (2013): 330 - 337.
MLA SİNDEL Dilşad Günümüzde ve gelecekte osteoporoz tedavisi. , 2013, ss.330 - 337.
AMA SİNDEL D Günümüzde ve gelecekte osteoporoz tedavisi. . 2013; 330 - 337.
Vancouver SİNDEL D Günümüzde ve gelecekte osteoporoz tedavisi. . 2013; 330 - 337.
IEEE SİNDEL D "Günümüzde ve gelecekte osteoporoz tedavisi." , ss.330 - 337, 2013.
ISNAD SİNDEL, Dilşad. "Günümüzde ve gelecekte osteoporoz tedavisi". (2013), 330-337.
APA SİNDEL D (2013). Günümüzde ve gelecekte osteoporoz tedavisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, 59(4), 330 - 337.
Chicago SİNDEL Dilşad Günümüzde ve gelecekte osteoporoz tedavisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 59, no.4 (2013): 330 - 337.
MLA SİNDEL Dilşad Günümüzde ve gelecekte osteoporoz tedavisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, vol.59, no.4, 2013, ss.330 - 337.
AMA SİNDEL D Günümüzde ve gelecekte osteoporoz tedavisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi. 2013; 59(4): 330 - 337.
Vancouver SİNDEL D Günümüzde ve gelecekte osteoporoz tedavisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi. 2013; 59(4): 330 - 337.
IEEE SİNDEL D "Günümüzde ve gelecekte osteoporoz tedavisi." Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, 59, ss.330 - 337, 2013.
ISNAD SİNDEL, Dilşad. "Günümüzde ve gelecekte osteoporoz tedavisi". Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi 59/4 (2013), 330-337.